Viva Biotech's Portfolio Company Riparian Signs an Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
- Riparian will receive up front & is eligible to receive milestones along with royalties on sales of resulting therapeutics. Pfizer also gets an exclusive right to a Riparian preclinical program
- Under the terms of the agreement, Pfizer will be responsible to support Riparian's efforts to discover drug targets leading to Vaso protection and also gets an option on such targets
- Additionally, the agreement focuses to accelerate the programs and developing therapies, discovering novel targets as well as designing and synthesis of compounds
Ref: PR Newswire | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.